BACKGROUND: Oncolytic adenoviral virotherapy (OV) is a highly promising approach for the treatment of glioblastoma multiforme (GBM). In practice, however, the approach is limited by poor viral distribution and spread throughout the tumor mass. METHODS: To enhance viral delivery, replication, and spread, we used a US Food and Drug Administration-approved neural stem cell line (NSC), HB1.F3.CD, which is currently employed in human clinical trials. HB1.F3.CD cells were loaded with an oncolytic adenovirus, CRAd-Survivin-pk7, and mice bearing various human-derived GBMs were assessed with regard to NSC migration, viral replication, and therapeutic efficacy. Survival curves were evaluated with Kaplan-Meier methods. All statistical tests were two-sided. RESULTS: Antiglioma activity of OV-loaded HB1.F3.CD cells was effective against clinically relevant human-derived glioma models as well as a glioma stem cell-enriched xenograft model. Median survival was prolonged by 34% to 50% compared with mice treated with OV alone (GBM43FL model median survival = 19.5 days, OV alone vs NSC + OV, hazard ratio of survival = 2.26, 95% confidence interval [CI] = 1.21 to 12.23, P = .02; GBM12 model median survival = 43.5 days, OV alone vs NSC + OV, hazard ratio of survival = 2.53, 95% CI = 1.21 to 10.38, P = .02). OV-loaded HB1.F3.CD cells were shown to effectively migrate to the contralateral hemisphere and hand off the therapeutic payload of OV to targeted glioma cells. In vivo distribution and migratory kinetics of the OV-loaded HB1.F3.CD cells were successfully monitored in real time by magnetic resonance imaging. OV-loaded NSCs retained their differentiation fate and were nontumorigenic in vivo. CONCLUSIONS: HB1.F3.CD NSCs loaded with CRAd-Survivin-pk7 overcome major limitations of OV in vivo and warrant translation in a phase I human clinical trial for patients with GBM.
BACKGROUND: Oncolytic adenoviral virotherapy (OV) is a highly promising approach for the treatment of glioblastoma multiforme (GBM). In practice, however, the approach is limited by poor viral distribution and spread throughout the tumor mass. METHODS: To enhance viral delivery, replication, and spread, we used a US Food and Drug Administration-approved neural stem cell line (NSC), HB1.F3.CD, which is currently employed in human clinical trials. HB1.F3.CD cells were loaded with an oncolytic adenovirus, CRAd-Survivin-pk7, and mice bearing various human-derived GBMs were assessed with regard to NSC migration, viral replication, and therapeutic efficacy. Survival curves were evaluated with Kaplan-Meier methods. All statistical tests were two-sided. RESULTS: Antiglioma activity of OV-loaded HB1.F3.CD cells was effective against clinically relevant human-derived glioma models as well as a glioma stem cell-enriched xenograft model. Median survival was prolonged by 34% to 50% compared with mice treated with OV alone (GBM43FL model median survival = 19.5 days, OV alone vs NSC + OV, hazard ratio of survival = 2.26, 95% confidence interval [CI] = 1.21 to 12.23, P = .02; GBM12 model median survival = 43.5 days, OV alone vs NSC + OV, hazard ratio of survival = 2.53, 95% CI = 1.21 to 10.38, P = .02). OV-loaded HB1.F3.CD cells were shown to effectively migrate to the contralateral hemisphere and hand off the therapeutic payload of OV to targeted glioma cells. In vivo distribution and migratory kinetics of the OV-loaded HB1.F3.CD cells were successfully monitored in real time by magnetic resonance imaging. OV-loaded NSCs retained their differentiation fate and were nontumorigenic in vivo. CONCLUSIONS:HB1.F3.CD NSCs loaded with CRAd-Survivin-pk7 overcome major limitations of OV in vivo and warrant translation in a phase I human clinical trial for patients with GBM.
Authors: Karen L Ring; Leslie M Tong; Maureen E Balestra; Robyn Javier; Yaisa Andrews-Zwilling; Gang Li; David Walker; William R Zhang; Anatol C Kreitzer; Yadong Huang Journal: Cell Stem Cell Date: 2012-06-07 Impact factor: 24.633
Authors: Jann N Sarkaria; Brett L Carlson; Mark A Schroeder; Patrick Grogan; Paul D Brown; Caterina Giannini; Karla V Ballman; Gaspar J Kitange; Abjahit Guha; Ajay Pandita; C David James Journal: Clin Cancer Res Date: 2006-04-01 Impact factor: 12.531
Authors: K S Aboody; A Brown; N G Rainov; K A Bower; S Liu; W Yang; J E Small; U Herrlinger; V Ourednik; P M Black; X O Breakefield; E Y Snyder Journal: Proc Natl Acad Sci U S A Date: 2000-11-07 Impact factor: 11.205
Authors: Hrvoje Miletic; Yvonne Fischer; Sara Litwak; Tsanan Giroglou; Yannic Waerzeggers; Alexandra Winkeler; Huongfeng Li; Uwe Himmelreich; Claudia Lange; Werner Stenzel; Martina Deckert; Harald Neumann; Andreas H Jacobs; Dorothee von Laer Journal: Mol Ther Date: 2007-04-24 Impact factor: 11.454
Authors: Ilya V Ulasov; Zeng B Zhu; Matthew A Tyler; Yu Han; Angel A Rivera; Andrey Khramtsov; David T Curiel; Maciej S Lesniak Journal: Hum Gene Ther Date: 2007-07 Impact factor: 5.695
Authors: Juli R Bagó; Onyi Okolie; Raluca Dumitru; Matthew G Ewend; Joel S Parker; Ryan Vander Werff; T Michael Underhill; Ralf S Schmid; C Ryan Miller; Shawn D Hingtgen Journal: Sci Transl Med Date: 2017-02-01 Impact factor: 17.956
Authors: Shengwen Calvin Li; Mustafa H Kabeer; Long T Vu; Vic Keschrumrus; Hong Zhen Yin; Brent A Dethlefs; Jiang F Zhong; John H Weiss; William G Loudon Journal: World J Stem Cells Date: 2014-09-26 Impact factor: 5.326
Authors: Julius W Kim; J Robert Kane; Jacob S Young; Alan L Chang; Deepak Kanojia; Shuo Qian; Drew A Spencer; Atique U Ahmed; Maciej S Lesniak Journal: Curr Protoc Hum Genet Date: 2015-04-01
Authors: Dou Yu; Omar F Khan; Mario L Suvà; Biqin Dong; Wojciech K Panek; Ting Xiao; Meijing Wu; Yu Han; Atique U Ahmed; Irina V Balyasnikova; Hao F Zhang; Cheng Sun; Robert Langer; Daniel G Anderson; Maciej S Lesniak Journal: Proc Natl Acad Sci U S A Date: 2017-07-10 Impact factor: 11.205
Authors: Julius W Kim; J Robert Kane; Jacob S Young; Alan L Chang; Deepak Kanojia; Ramin A Morshed; Jason Miska; Atique U Ahmed; Irina V Balyasnikova; Yu Han; Lingjiao Zhang; David T Curiel; Maciej S Lesniak Journal: Hum Gene Ther Date: 2015-08-11 Impact factor: 5.695